

# Chris Parker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/723549/publications.pdf>

Version: 2024-02-01

46  
papers

4,136  
citations

430442

18  
h-index

276539

41  
g-index

47  
all docs

47  
docs citations

47  
times ranked

5841  
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2022, 168, 75-82.	0.3	10
2	False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS. <i>European Urology</i> , 2021, 79, 20-29.	0.9	13
3	Timing of Postoperative Radiation Therapy After Radical Prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1132-1134.	0.4	3
4	What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort. <i>European Urology</i> , 2020, 78, 163-170.	0.9	60
5	The Emerging Role of Local Therapy in Metastatic Prostate Cancer. <i>Current Oncology Reports</i> , 2020, 22, 2.	1.8	7
6	Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial. <i>Journal of Urology</i> , 2020, 203, 100-107.	0.2	9
7	Patterns of recurrence after prostate bed radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 141, 174-180.	0.3	19
8	A four-group urine risk classifier for predicting outcomes in patients with prostate cancer. <i>BJU International</i> , 2019, 124, 609-620.	1.3	30
9	A Tool for Shared Decision Making on Referral for Prostate Biopsy in the Primary Care Setting: Integrating Risks of Cancer with Life Expectancy. <i>Journal of Personalized Medicine</i> , 2019, 9, 19.	1.1	2
10	Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancer. <i>Clinical and Translational Radiation Oncology</i> , 2018, 10, 1-6.	0.9	1
11	Total energy expenditure and vigorous-intensity physical activity are associated with reduced odds of reclassification among men on active surveillance. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 187-195.	2.0	7
12	Management of Men with Prostate-specific Antigen Failure After Prostate Radiotherapy: The Case Against Early Androgen Deprivation. <i>European Urology</i> , 2018, 73, 521-523.	0.9	4
13	National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection – recommendations from a UK consensus meeting. <i>BJU International</i> , 2018, 122, 13-25.	1.3	106
14	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	0.9	488
15	Re: Effect of Longer-interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Patients with Bone Metastases. <i>European Urology</i> , 2018, 73, 304.	0.9	0
16	Salvage Treatment After Radical Prostatectomy. <i>European Urology</i> , 2018, 73, 166-167.	0.9	1
17	Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. <i>Health Technology Assessment</i> , 2018, 22, 1-176.	1.3	70
18	Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). <i>BJU International</i> , 2017, 119, 522-529.	1.3	18

#	ARTICLE	IF	CITATIONS
19	Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. <i>Lancet, The</i> , 2017, 389, 815-822.	6.3	2,267
20	Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 678-684.e1.	0.9	16
21	Diagnostic accuracy of the PROMIS study – Authors’ reply. <i>Lancet, The</i> , 2017, 390, 362.	6.3	5
22	Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. <i>Eur Urol</i> 2016;70:21–30. <i>European Urology</i> , 2016, 70, e17.	0.9	8
23	TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. <i>Health Technology Assessment</i> , 2016, 20, 1-288.	1.3	29
24	PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. <i>European Urology</i> , 2015, 67, 795-802.	0.9	195
25	Reply from Authors re: Camillo Porta, Sergio Bracarda, Romano Danesi. Steroids in Prostate Cancer: The Jury Is Still Out... and Even More Confused. <i>Eur Urol</i> 2015;67:680–1. <i>European Urology</i> , 2015, 67, 681-682.	0.9	2
26	A Randomised Phase 2 Trial of Dexamethasone Versus Prednisolone in Castration-resistant Prostate Cancer. <i>European Urology</i> , 2015, 67, 673-679.	0.9	80
27	Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 133-143.	2.0	23
28	The Evolution of Active Surveillance for Prostate Cancer. <i>European Urology</i> , 2015, 68, 822-823.	0.9	4
29	Radium-223 in the Treatment of Osteoblastic Metastases: A Critical Clinical Review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 898-906.	0.4	49
30	Use of radium-223 in men with metastatic castration-resistant prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 723-5.	0.3	1
31	A near miss for prostate cancer immunotherapy. <i>Lancet Oncology, The</i> , 2014, 15, 669-671.	5.1	5
32	Can we deliver randomized trials of focal therapy in prostate cancer?. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 482-491.	12.5	60
33	Progress in the Treatment of Advanced Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 117-131.	1.8	31
34	Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 273-279.	3.0	138
35	What (if anything) to do about low-risk prostate cancer. <i>Lancet, The</i> , 2012, 379, 1078-1080.	6.3	5
36	Multiparametric magnetic resonance imaging in the diagnosis and characterisation of prostate cancer: The PROMIS study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 62-62.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.. Journal of Clinical Oncology, 2012, 30, 8-8.	0.8	55
38	Androgen deprivation before prostate radiotherapy: how long is long enough?. Lancet Oncology, The, 2011, 12, 411-412.	5.1	0
39	Re: Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer. European Urology, 2011, 60, 1306.	0.9	0
40	Re: Ute Ganswindt, Arnulf Stenzl, Michael Bamberg and Claus Belka. Adjuvant Radiotherapy for Patients with Locally Advanced Prostate Cancer – A New Standard? Eur Urol 2008;54:528-42. European Urology, 2009, 55, e47.	0.9	0
41	SCREENING FOR PROSTATE CANCER APPEARS TO WORK, BUT AT WHAT COST?. BJU International, 2009, 104, 290-292.	1.3	5
42	Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU International, 2007, 99, 1376-1379.	1.3	130
43	A MORE SELECTIVE APPROACH TO PROSTATE BIOPSY COULD BE A SAFE AND EFFECTIVE FORM OF PROSTATE CANCER PREVENTION?. BJU International, 2007, 100, 488-490.	1.3	1
44	Prolonging survival in prostate cancer: chemotherapy will have an important role. BJU International, 2005, 96, 2-3.	1.3	0
45	The Scandinavian prostate cancer group study: the case for conservative management. BJU International, 2005, 96, 952-953.	1.3	2
46	Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncology, The, 2004, 5, 101-106.	5.1	176